Русский
Changes in TLR2 and TLR4 gene expression in patients with ischemic stroke
DOI: https://dx.doi.org/10.18565/pharmateca.2022.13.98-104
E.A. Koltsova, E.A. Petrova, V.V. Grechenko, L.V. Gankovskaya
1) Department of Neurology, Neurosurgery and Medical Genetics, Faculty of General Medicicne, Pirogov Russian National Research Medical University, Moscow, Russia; 2) Department of Immunology, Biomedical Faculty, Pirogov Russian National Research Medical University, Moscow, Russia
Background. The study of atherosclerosis and its complications is one of the priority areas of scientific research in the field of neurology and fundamental sciences. A lot of research has expanded the understanding of the involvement of the immune response, inflamma- tory reactions in the pathogenesis of ischemic stroke (IS). New information about the role of innate immunity in the brain response to ischemia is emerging.
Objective. Determination of the TLR2 and TLR4 gene expression in patients with IS and healthy individuals.
Methods. The study included 28 patients with ischemic stroke and a comparison group consisting of 18 healthy individuals.
Results. It was found that the TLR4 gene expression significantly exceeded the TLR2 gene expression on days 1, 3, and 7 after the onset of IS. It was shown that on the 1st day of disease, the expression of the studied genes significantly exceeded their expression in the control group. At the same time, on the 3rd day, the TLR2 and TLR4 gene expression somewhat decreased. However, on the 7th day, an increase in expression was noted again. The available literature data suggest that the decrease in the TLR2 and TLR4 gene expression on the 3rd day after the onset of a stroke may be associated with the implementation of neuroprotection mechanisms, in which HSP70, HSP27, miR-21, miR-24, and miR- 223 can play a leading role. Increased TLR2 and TLR4 gene expression on day 7 may be associated with delayed death of brain cells in the postischemic period.
Conclusion. The study obtained data on changes in the TLR2 and TLR4 gene expression in patients with IS over time, which makes it
possible to assess changes in the activity of the inflammatory process in them at the system level. TLRs make a great contribution to the course of IS, which justifies the need for further research into the role of innate immunity in the development of IS in order to elaborate and implement new approaches to prognosis and therapy.
Objective. Determination of the TLR2 and TLR4 gene expression in patients with IS and healthy individuals.
Methods. The study included 28 patients with ischemic stroke and a comparison group consisting of 18 healthy individuals.
Results. It was found that the TLR4 gene expression significantly exceeded the TLR2 gene expression on days 1, 3, and 7 after the onset of IS. It was shown that on the 1st day of disease, the expression of the studied genes significantly exceeded their expression in the control group. At the same time, on the 3rd day, the TLR2 and TLR4 gene expression somewhat decreased. However, on the 7th day, an increase in expression was noted again. The available literature data suggest that the decrease in the TLR2 and TLR4 gene expression on the 3rd day after the onset of a stroke may be associated with the implementation of neuroprotection mechanisms, in which HSP70, HSP27, miR-21, miR-24, and miR- 223 can play a leading role. Increased TLR2 and TLR4 gene expression on day 7 may be associated with delayed death of brain cells in the postischemic period.
Conclusion. The study obtained data on changes in the TLR2 and TLR4 gene expression in patients with IS over time, which makes it
possible to assess changes in the activity of the inflammatory process in them at the system level. TLRs make a great contribution to the course of IS, which justifies the need for further research into the role of innate immunity in the development of IS in order to elaborate and implement new approaches to prognosis and therapy.
Keywords: TLR2, TLR4, innate immunity, Toll-like receptors, inflammation, ischemic stroke, atherosclerosis
About the Autors
Corresponding author: Elizaveta A. Petrova, Department of Neurology, Neurosurgery and Medical Genetics, Faculty of General Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; 6332011@mail.ru
Similar Articles
